Invest Securities confirms its neutral opinion on Diasorin and lowers its target price to E90 (from E91).

The analyst believes that on Friday, Diasorin ended 2023 with another disappointing performance, both in terms of growth and margins.

Once again, the robustness of the Immunodiagnostic franchise failed to offset the underperformance of the Molecular Diagnostics and LTG franchises. The Group has renewed its 2024 targets, with which we are in line", says the analyst.

Premium positioning in the immunoassay segment is no longer sufficient to outperform peers at a justified valuation. Lastly, visibility on the potential contribution of the pipeline is still limited', says Invest Securities.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.